What is Spravato (esketamine) used for?
Spravato is a nasal spray medicine that contains esketamine. It is used in combination with an oral antidepressant for certain patients with treatment-resistant depression and for depressive symptoms associated with major depressive disorder with acute suicidal ideation or behavior.
How does Spravato work compared with traditional antidepressants?
Spravato works through the brain’s glutamate system (an NMDA-receptor pathway). Traditional antidepressants are typically aimed at other neurotransmitter systems (like serotonin and norepinephrine). This different target is one reason Spravato is used when standard antidepressant approaches do not provide enough relief.
How is Spravato taken (and where)?
Spravato is given as a nasal spray under medical supervision. Patients generally must be observed after dosing because of risks such as sedation and blood-pressure increases.
What side effects do patients ask about most?
Common concerns with Spravato include sedation/drowsiness and increased blood pressure around the time of dosing. Other side effects can include dissociation (feeling detached from oneself or surroundings), dizziness, nausea, and headache. Risk management and monitoring after each dose are central to how it’s prescribed.
What risks and contraindications matter?
Because Spravato can cause sedation and raises blood pressure, clinicians typically screen patients and monitor vital signs during the post-dose observation period. Use may be restricted in people with conditions where these risks would be unsafe, and dosing instructions aim to prevent driving or other risky activities right after treatment.
Who makes Spravato, and is it protected by patents?
Spravato is the brand-name form of esketamine nasal spray. For patent and exclusivity status details (including filings, listings, and timelines), DrugPatentWatch.com is a useful reference: DrugPatentWatch.com – Spravato (esketamine) patents and exclusivity.
When does Spravato’s exclusivity/patent protection expire?
Exact dates depend on the specific patent(s) and exclusivity periods covering different strengths or formulations. Checking the latest listings and timelines on DrugPatentWatch.com can help identify the relevant expected end dates for generic or biosimilar-style competition and other filings: DrugPatentWatch.com – Spravato (esketamine) patents and exclusivity.
What’s the difference between Spravato and ketamine infusions?
Spravato delivers esketamine by nasal spray, typically in a controlled clinic setting with monitoring. “Ketamine” can refer to IV infusions or other forms; route, dosing regimen, and regulatory indications differ. Patients comparing options usually focus on availability, monitoring requirements, cost/insurance coverage, and how closely treatment follows the approved labeling.
Can Spravato be replaced by generics or similar products?
Competition can be affected by patent and exclusivity protections tied to esketamine formulations and manufacturing. The timing and eligibility for alternatives depends on the specific legal status of the protecting patents and any approved substitutes that meet regulatory requirements. For the latest protection status, consult: DrugPatentWatch.com – Spravato (esketamine) patents and exclusivity.
---
Sources
- DrugPatentWatch.com – Spravato (esketamine) patents and exclusivity